Get started
Author

Zhuo Cheng

Clinical and biomarker analyses of sintilimab plus gemcitabine and cisplatin as first-line treatment for patients with advanced biliary tract cancer
2023 · Tian-mei Zeng, Guang Yang, et al. · Nature Communications · 41
PDF
Bortezomib in previously treated phosphatase and tension homology‐deficient patients with advanced intrahepatic cholangiocarcinoma: An open‐label, prospective and single‐centre phase II trial
2024 · Tian‐mei Zeng, Tian‐yi Jiang, et al. · Clinical and Translational Medicine · 6
Potassium Chloride-induced Acute Hemorrhagic Erosive Gastropathy
2025 · Zhuo Cheng, Zhijie Xu · The American Journal of Gastroenterology
Comorbidity Patterns and Influencing Factors in Elderly Chronic Disease Patients: A Five-Year Retrospective Study
2025 · Yugao Wu, Rongyue Li, et al. · Research Square
Superior survival benefits of triple combination immunotherapy compared to standard chemotherapy as second-line treatment for advanced biliary tract cancer: a retrospective analysis
2024 · Peipei Shang, Heming Xu, et al. · Frontiers in Oncology
PDF
Toripalimab combined with anlotinib as the second-line treatment for advanced hepatocellular carcinoma patients: a prospective, single arm phase II clinical study
2023 · Wei Wei, Xiyun Chen, et al. · Research Square
PDF
Sintilimab plus gemcitabine and cisplatin as a first-line treatment for patients with advanced biliary tract cancer: A biomolecular exploratory, phase II clinical trial.
2023 · Zhen-gang Yuan, Tian-mei Zeng, et al. · Journal of Clinical Oncology
WITHDRAWN: Bortezomib in PTEN-deficient patients with advanced intrahepatic cholangiocarcinoma: an open-label, prospective, phase II trial
2023 · tianmei zeng, Tian-yi Jiang, et al. · Research Square
Works count: 8
Citation count: 47
H-index: 2
I10-index: 1
Year
Topic
Type